Aldeyra therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Aldeyra therapeutics Contact Number

Contact Aldeyra Therapeutics Inc

2 hours ago Aldeyra.com Show details

(781) 761-4904

For more information, please contact us. Aldeyra Therapeutics 131 Hartwell Avenue, Suite 320 Lexington, MA 02421. Telephone: (781) 761-4904 Fax: (339) 674-6495

Category: Contact SupportShow more

Aldeyra Therapeutics, Inc.

4 hours ago Aldeyra.com Show details

At Aldeyra, we’re a pioneer in the development of medicines to improve the lives of patients with immune-mediated diseases. Our pipeline of drug candidates is focused on inhibiting inflammatory cells linked to ocular and systemic conditions not adequately addressed by current treatments.

Category: Contact NumberShow more

Aldeyra Therapeutics Crunchbase Company Profile & Funding

Just Now Crunchbase.com Show details

(646) 536-7009

Contact Email [email protected] Phone Number (646) 536-7009 Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.

Founded: 2004

Category: Contact NumberShow more

Privacy Policy Aldeyra Therapeutics Inc.

9 hours ago Aldeyra.com Show details

(781) 761-4904

Contacting Us. If there are any questions regarding this privacy policy you may contact us through the form available here or by using one of the methods listed below. Address: Aldeyra Therapeutics. 131 Hartwell Avenue, Suite 320. Lexington, MA 02421. Telephone: (781) 761-4904. Fax: (339) 674-6495.

Estimated Reading Time: 9 mins

Category: Contact NumberShow more

Aldeyra Therapeutics Expands Retinal Disease Pipeline with

1 hours ago Ir.aldeyra.com Show details

781-761-4904

Corporate Contact: David McMullin Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. 218 [email protected]aldeyra.com. Investor Contact: Chris Brinzey Westwicke Partners Tel: 339-970-2843 [email protected]

Category: Contact NumberShow more

Leadership Aldeyra Therapeutics Inc.

1 hours ago Aldeyra.com Show details

Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the board of directors of Evoke Pharma, Inc. and F-star Therapeutics, Inc., both of which are publicly traded healthcare companies.

Category: Contact NumberShow more

Investor Relations Aldeyra Therapeutics, Inc.

3 hours ago Ir.aldeyra.com Show details

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the companyʼs lead product candidates, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic

Category: Contact NumberShow more

Aldeyra Therapeutics Company Profile Office Locations

7 hours ago Craft.co Show details

Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes Content Import Thu, 07/01/2021 - 08:01 Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes July 1, 2021 This release is a backfill from a News Wire Genera…

Category: Contact NumberShow more

Aldeyra Therapeutics email format Aldeyra Therapeutics

3 hours ago Aeroleads.com Show details

Aldeyra therapeutics uses 2 email formats: 1. (f)(lastname) ([email protected]aldeyra.com). Enter a name to find and verify an email

Category: Contact NumberShow more

Reproxalap for Dry Eye Disease Aldeyra Therapeutics, Inc.

9 hours ago Aldeyra.com Show details

Aldeyra intends to advance 0.25% topical ocular reproxalap, our lead RASP inhibitor, for the treatment of dry eye disease. Clinical Results for Dry Eye Disease In a Phase 2b clinical trial, Aldeyra’s lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease.

Category: Contact NumberShow more

Aldeyra Therapeutics acquires Helio Vision

3 hours ago Biospectrumasia.com Show details

Aldeyra Therapeutics, a biotechnology company developing and commercializing next-generation medicines for immune-mediated diseases has announced that it has acquired Helio Vision, a privately held biotechnology company. Contact Number * +Country Code-Phone Number(xxx-xxxxxxx)

Category: Contact NumberShow more

Aldeyra Therapeutics Reports SecondQuarter 2021 Financial

6 hours ago Ir.aldeyra.com Show details

781-761-4904

Corporate Contact: Joshua Reed Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. 218 [email protected]aldeyra.com Investor & Media Contact: Scott Solomon Sharon Merrill Associates, Inc. Tel: 857-383-2409 [email protected] Source: Aldeyra Therapeutics, Inc.

Category: Contact NumberShow more

Contact Us Akari Therapeutics

5 hours ago Akaritx.com Show details

20-8004-0261

Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.

Category: Contact SupportShow more

Aldeyra Therapeutics Reaches Agreement with the US Food

7 hours ago Us.acrofan.com Show details

781-761-4904

Corporate Contact: David McMullin Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. 218 [email protected]aldeyra.com Investor & Media Contact: Scott Solomon Sharon Merrill Associates, Inc. Tel: 617-542-5300 [email protected]

Category: Contact NumberShow more

EX99.1

4 hours ago Sec.gov Show details

781-761-4904

The Conference ID number is 4968588. Due to expected high demand, please dial in at least 15 minutes prior to the start time. About Aldeyra Therapeutics, Inc. Corporate Contact: Joshua Reed . Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. 218 . [email protected]aldeyra.com . Investor & Media Contact: Scott Solomon . Sharon Merrill Associates

Category: Contact NumberShow more

Aldeyra Therapeutics Schedules Webcast and Conference Call

9 hours ago Ir.aldeyra.com Show details

The Conference ID number is 4968588. A live webcast of the conference call will also be available on the Investors & Media page of the company’s corporate website at https://ir.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days. About Aldeyra Therapeutics, Inc.

Category: Contact NumberShow more

Aldeyra Therapeutics, Inc. Announces Pricing of Public

5 hours ago Businesswire.com Show details

781-761-4904

Corporate Contact: David McMullin Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. 218 [email protected]aldeyra.com Investor & Media Contact: Scott Solomon Sharon Merrill Associates, Inc. Tel: 617-542

Category: Contact NumberShow more

Aldeyra Therapeutics Inc – Material Contracts – BamSEC

4 hours ago Bamsec.com Show details

from 10-K 69 pages This Sublease, Made and Entered Into as of the 7th Day of March 2016, by and Between Planck, LLC, a Delaware Limited Liability Company, Having an Office and Place of Business C/O Patch Media, 134 W. 29th St., 11th F1, New York, Ny 10001 Hereinafter Called “Sublessor”, and Aldeyra Therapeutics, Inc., a Delaware Corporation, …

Category: Contact NumberShow more

Aldeyra Therapeutics Reports SecondQuarter 2021 Financial

9 hours ago Finance.yahoo.com Show details

The Conference ID number is 4968588. Due to expected high demand, please dial in at least 15 minutes prior to the start time. Corporate Contact: Joshua Reed Aldeyra Therapeutics, Inc. Tel: 781

Category: Contact NumberShow more

Aldeyra Therapeutics, Inc. (ALDX) Company Profile

6 hours ago Stockanalysis.com Show details

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis.

Category: Contact NumberShow more

Aldeyra Therapeutics Announces ThirdQuarter 2020

7 hours ago Ir.aldeyra.com Show details

Contact Us; Search. Press Release Details . Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update. November 5, 2020 . The Conference ID number is 5472726. Due to the expected high demand on our conference provider, please plan to dial in to the call at least 15 minutes prior to the start time.

Category: Contact NumberShow more

Aldxdef14a_20210608.htm

1 hours ago Sec.gov Show details

April 14, 2021 . You are cordially invited to attend the 2021 Annual Meeting of Stockholders of Aldeyra Therapeutics, Inc. that will be held on Tuesday, June 8, 2021 at 8:00 a.m. local time, at the offices of Aldeyra Therapeutics, Inc., 131 …

Category: Contact NumberShow more

ALDEYRA THERAPEUTICS, INC. : Shareholders Board Members

5 hours ago Marketscreener.com Show details

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in developing immune-modulating therapies to treat ocular and systemic diseases. The Company's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC).

Category: Contact NumberShow more

Aldexa Therapeutics Crunchbase Company Profile & Funding

9 hours ago Crunchbase.com Show details

Aldexa Therapeutics, Inc. was formerly known as Neuron Systems, Inc. The. company was incorporated in 2004 and is based in Burlington, Massachusetts. The company changed its name to Aldeyra Therapeutics, Inc. on March 17, 2014. Aldeyra held an initial public offering on May 7, …

Category: Contact NumberShow more

Aldeyra Therapeutics, Inc. (ALDX) Company Profile & Facts

4 hours ago Finance.yahoo.com Show details

See the company profile for Aldeyra Therapeutics, Inc. (ALDX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives

Category: Contact NumberShow more

The TRANQUILITY Trial: Clinical Trial to Assess the

7 hours ago Clinicaltrials.gov Show details

Aldeyra Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT04674358 Other Study ID Numbers: ADX-102-DED-019 : First Posted: December 19, 2020 Key Record Dates: Last Update Posted: April 14, 2021 Last Verified: April 2021

Category: Contact NumberShow more

Aldeyra Therapeutics, Inc. Home Facebook

4 hours ago Facebook.com Show details

Contact Aldeyra Therapeutics, Inc. on Messenger. www.aldeyra.com. Biotechnology Company · Pharmaceutical Company. Page Transparency See More. Facebook is showing information to help you better understand the purpose of a Page. See actions taken by the people who manage and post content. Page created - August 6, 2015.

Category: Home PhoneShow more

Aldeyra Therapeutics, Inc. 10K Mar. 12, 2020 4:31 PM

9 hours ago Seekingalpha.com Show details

Commission File Number 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 20-1968197 (State or other jurisdiction allergic contact dermatitis

Category: Contact NumberShow more

DEF 14A SEC

5 hours ago Sec.gov Show details

Table of Contents . April 24, 2017 . You are cordially invited to attend the 2017 Annual Meeting of Stockholders of Aldeyra Therapeutics, Inc. that will be held on Thursday, June 8, 2017 at 10:00 a.m. local time, at the offices of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, One Marina Park Drive, Suite 900, Boston, MA 02210.

Category: Contact NumberShow more

PERCEPTIVE ADVISORS LLC SC 13G/A Filing Concerning ALDX on

8 hours ago Whalewisdom.com Show details

Aldeyra Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 01438T 10 6 (CUSIP Number) July 9, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c)

Category: Contact NumberShow more

Aldeyra Therapeutics to Host Conference Call and Webcast

7 hours ago Finance.yahoo.com Show details

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, January 7, 2021, to discuss top-line symptom, redness, and Schirmer’s test

Category: Contact NumberShow more

Is Aldeyra Therapeutics Inc (ALDX) A Good Stock To Buy?

Just Now Finance.yahoo.com Show details

More specifically, Perceptive Advisors was the largest shareholder of Aldeyra Therapeutics Inc (NASDAQ:ALDX), with a stake worth $103.4 million reported as of …

Category: Contact NumberShow more

Aldeyra Therapeutics, Inc. AnnualReports.com

2 hours ago Annualreports.com Show details

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic

Category: Contact NumberShow more

A Clinical Trial to Assess Subjects With Dry Eye Disease

7 hours ago Clinicaltrials.gov Show details

Aldeyra Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT04971031 Other Study ID Numbers: ADX-102-DED-024 : First Posted: July 21, 2021 Key Record Dates: Last Update Posted: July 22, 2021 Last Verified: July 2021 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No

Category: Contact NumberShow more

ALDX Insider Trading Aldeyra Therapeutics Inc. Form 4

2 hours ago Secform4.com Show details

020-03-02

Aldeyra Therapeutics Inc. ALDX: Brady Todd C CEO: 250,000: $0: 902,216 (Direct) View: 2020-03-02 Option Award: 2020-03-04 7:44 pm: N/A 2030-03-01: Aldeyra Therapeutics Inc. ALDX: Brady Todd C CEO: 250,000: $0: 250,000 (Direct) View: 2020-03-02 Option Award: 2020-03-04 7:44 pm: N/A N/A: Aldeyra Therapeutics Inc. ALDX: Brady Todd C CEO: 450,865

Category: Contact NumberShow more

ALDEYRA THERAPEUTICS, INC. : ALDX Stock Price

7 hours ago Marketscreener.com Show details

81,4%. More Financials. Company. Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Category: Contact NumberShow more

Aldeyra Therapeutics Inc. (NASDAQ: ALDX): What Value Is It

4 hours ago Marketingsentinel.com Show details

Aldeyra Therapeutics Inc. (NASDAQ:ALDX)’s traded shares stood at 0.41 million during the last session, with the company’s beta value hitting 1.71. At the close of trading, the stock’s price was $9.04, to imply an increase of 2.49% or $0.22 in intraday trading. The ALDX share’s 52-week high r

Category: Contact NumberShow more

Will Aldeyra Therapeutics Inc (ALDX) Beat the Rest of the

9 hours ago Investorsobserver.com Show details

Aldeyra Therapeutics Inc is near the top in its sector according to InvestorsObserver. ALDX gets an overall rating of 33. That means it scores higher than 33% of stocks. Aldeyra Therapeutics Inc gets a 70 rank in the Healthcare sector. Healthcare is number 6 out of 11 sectors.

Category: Contact NumberShow more

A Clinical Trial to Evaluate the Safety, Tolerability, and

1 hours ago Clinicaltrials.gov Show details

Aldeyra Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT04908514 Other Study ID Numbers: ADX-629-PS-001 : First Posted: June 1, 2021 Key Record Dates: Last Update Posted: June 1, 2021 Last Verified: May 2021 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No

Category: Contact NumberShow more

ALDX SEC Filings & 10K Form (Aldeyra Therapeutics)

8 hours ago Marketbeat.com Show details

Aldeyra Therapeutics (Filer) Form S-8. Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans. 03/11/2021. 6:35 AM. Aldeyra Therapeutics (Filer) Form 8-K. Current report pursuant to Section 13 or 15 (d) 02/16/2021.

Category: Contact NumberShow more

Is Aldeyra Therapeutics Inc (ALDX) A Good Stock To Buy

5 hours ago Insidermonkey.com Show details

Compared to these stocks Aldeyra Therapeutics Inc (NASDAQ:ALDX) is more popular among hedge funds. Our overall hedge fund sentiment score for ALDX is 81.8. Stocks with higher number of hedge fund

1. Author: Asma UL Husna

Category: Contact NumberShow more

Nancy MillerRich BioTheryX, Inc.

3 hours ago Biotheryx.com Show details

She is currently a director of Aldeyra Therapeutics, Inc., Intercept Pharmaceuticals, Kadmon Holdings, Inc., and 4D Molecular Therapeutics, Inc., as well as a board member of a number of private and not-for-profit entities. She received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York.

Category: Contact NumberShow more

Yvonne Eaton QA Manager Rubius Therapeutics LinkedIn

Just Now Linkedin.com Show details

Supervisor/Associate Manager, QC. Amgen. Jan 2001 - Apr 20032 years 4 months. West Greenwich, RI.

Title: QA Manager at Rubius …
Location: Berkley, Massachusetts
Connections: 415

Category: Contact NumberShow more

Aldeyra Stock Today ALDX Macroaxis

3 hours ago Macroaxis.com Show details

Aldeyra Therapeu is trading at 8.62 as of the 13th of October 2021; that is 0.23% increase since the beginning of the trading day. The stock's open price was 8.6. Get the latest Aldeyra Therapeu detailed stock quotes, stock trade data, stock price info, and performance analysis, including Aldeyra Stock investment advice, charts, stats and more.

Category: Contact NumberShow more

What is Aldeyra Therapeu Valuation? (NASDAQ:ALDX) Macroaxis

7 hours ago Macroaxis.com Show details

Aldeyra Therapeu shows a prevailing Real Value of $12.71 per share. The current price of the firm is $8.99. At this time, the firm appears to be undervalued.Our model approximates the value of Aldeyra Therapeu from analyzing the firm fundamentals such as current valuation of 579.93 M, and Return On Equity of (45.98) % as well as examining its technical indicators and Probability …

Category: Contact NumberShow more

Exceptionally Robust Asthma Pipeline with More Than 100

7 hours ago Finance.yahoo.com Show details

1 hour ago · Aldeyra Therapeutics. II. Aldehyde inhibitors. Oral. there has been a significant increase in the number of morbidity and mortality due to asthma. CONTACT: Contact Us Shruti Thakur info

Category: Contact NumberShow more

Exceptionally Robust Asthma Pipeline with More Than 100+

4 hours ago Globenewswire.com Show details

1 hour ago · Aldeyra Therapeutics: II : Aldehyde inhibitors : there has been a significant increase in the number of morbidity and mortality due to asthma. Contact Us Shruti Thakur [email protected]

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is aldeyra therapeutics?

Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing, and commercializing next-generation medicines that treat immune-mediated diseases.

How does aldeyra therapeutics help the immune system?

At Aldeyra, we’re a pioneer in the development of medicines to improve the lives of patients with immune-mediated diseases. Our pipeline of drug candidates is focused on inhibiting inflammatory cells linked to ocular and systemic conditions not adequately addressed by current treatments.

What are the risks and uncertainties of aldeyra therapeutics?

Actual results or trends could differ materially from those contemplated by these forward-looking statements. For more information, please refer to the risk factors discussed in Aldeyra's periodic filings with the SEC, including the most recent Form 10-Q or 10-K.

Which is the best aldeyra drug for dry eye?

Aldeyra intends to advance 0.25% topical ocular reproxalap, our lead RASP inhibitor, for the treatment of dry eye disease. Clinical Results for Dry Eye Disease In a Phase 2b clinical trial, Aldeyra’s lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease.

Brand New Updated

Popular Brands

Amazon
Abbvie
Aia
Asml
Amgen
Att
Apple
Adobe
Aptar
Acc
Adidas
Aak
Aes